Teleflex has announced new research findings reinforcing the long-term durability of prostatic urethral lift (PUL) with the UroLift system and lower complication rates compared to other minimally invasive procedures for men with enlarged prostate, also called benign prostatic hyperplasia (BPH). Results were presented at the Annual Meeting of the American Urological Association (AUA; April 28–May 1, Chicago, USA).
“Arriving at the intersection of effective BPH treatment, patient priorities and available technology can be a daunting task,” said Olly Kayes, honorary senior lecturer at the University of Leeds (Leeds, UK) and primary investigator of the PULSAR study. “These new analyses show that the UroLift system offers unique benefits for many men searching for long-term relief of burdensome symptoms affecting their quality of life. The UroLift system can be an excellent option for patients seeking quick and durable symptom improvement with preservation of sexual function and low risk of serious complications.”
Key findings from the studies presented are:
Early treatment prior to severe symptoms positively impacts long-term durability
- Pooled outcomes in more than 330 UroLift system subjects treated in a controlled setting were analysed and reported by Claus Roehrborn et al.
- PUL with the UroLift system was durable in most subjects at one and five years. 13.7% of subjects needed surgical retreatment at five years, which is consistent with the five-year surgical retreatment rates reported in the LIFT study (13.6%).
- Treatment earlier in the disease continuum, indicated by factors such as better overall International Prostate Symptom Score (IPSS) and quality of life (QoL) scores at baseline, facilitates long-term durability.
Earlier intervention in patients with urinary retention increases the likelihood of becoming catheter-independent after treatment
- The PULSAR study (n=51), reported by Olly Kayes et al, prospectively examined 12-month outcomes of the UroLift system treatment in subjects with urinary retention. Results were compared to 388 retention patients in the real-world retrospective study.
- After treatment with the UroLift system, 73% of controlled study subjects and 80% of real-world study subjects were catheter- and surgery-free at 12 months; success was associated with higher voiding efficiency during the perioperative period.
- Variables that influenced success included age under 70 years at procedure, lower baseline prostate-specific antigen (PSA) and post-void residual (PVR) levels, and shorter pre-procedural catheter duration.
- These data may help providers to better understand results after the UroLift system procedure and enable more men with urinary retention to obtain safe and effective BPH treatment.
“We are in the midst of a paradigm shift in the BPH landscape,” said Kevin Hardage, president and general manager of Teleflex Interventional Urology. “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before. The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift system as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”
